ArticleAmerican journal of cancer research2025
The impact of telemedicine on racial and ethnic disparities in oncologic care during the COVID-19 pandemic.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Codification of COVID-19-era use of telemedicine as a permanent feature of US healthcare has been discussed as it may increase accessibility and equity. This study assesses whether telemedicine is associated with improved differential access to cancer care for racial and ethnic minorities. We conducted a cross-sectional analysis of the National Health Interview Survey from July 2020 to December 2021 and estimated prevalence of telemedicine utilization in both the study population (N=46,799) and in a subgroup of cancer patients (N=7,784). Complex survey-weighted multivariable Poisson regression identified patient-level predictors and estimated risk ratios (RR) for telemedicine receipt. Two-way interaction between cancer type and race and ethnicity assessed effect modification. Telemedicine prevalence was 35.5% [95% CI: 34.8%-36.2%] for the overall study population and 48.7% [95% CI: 47.0%-50.4%] for cancer patients. Weighted multivariable Poisson regression revealed that non-Hispanic Black (NHB) and non-Hispanic Asian (NHA) individuals had lower receipt compared to non-Hispanic White (NHB RR: 0.87, 95% CI: [0.83-0.92], P<0.01; NHA RR: 0.8, 95% CI: [0.74-0.86], P<0.01). This racial and ethnic disparity disappeared among cancer patients. Adjusted risk difference (ARD) analysis indicated no difference in decreased telemedicine utilization by cancer type except for breast cancer (NHB ARD: -0.16, 95% CI: [-0.27-(-0.05)], P=0.01) and lymphoma (Other ARD: -0.36, 95% CI: [-0.72-(-0.01)], P=0.05). Racial and ethnic disparities in telemedicine utilization decreased for cancer patients compared to the overall population. While racial and ethnic disparities persisted in two oncologic subgroups, telemedicine overall improved access and may increase equity in oncologic care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.